Targeting IgE-producing B cells to treat allergic diseases
Official title: Bispecific antibody targeting IgE-producing B cells for treating allergic diseases
Funded at Cellergy Pharma · NIH-11069714 · Data updated 2026-11-12
This study is testing a new antibody drug that aims to safely target and remove the B cells that cause allergies, with the hope of providing a lasting solution for people with severe allergic diseases.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cellergy Pharma NIH-funded |
| Lab location | 1 site (Wilmington, UNITED STATES) |
| Project start | February 1, 2025 |
| Project end | January 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $300,000 |
| NIH project number | 1R41AI188995-01 |
| Project ID | NIH-11069714 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals suffering from severe allergic diseases, such as asthma or food allergies, particularly those who have not responded well to existing treatments.
✕Less likely to help
Patients with mild allergies or those who do not produce IgE may not benefit from this research.
What this research studies
This research focuses on developing a new antibody drug that specifically targets and eliminates B cells responsible for producing IgE, a key player in allergic reactions. By using immunocompromised mouse models, the researchers aim to assess the effectiveness and safety of this innovative treatment approach. The goal is to provide a long-lasting solution for patients suffering from severe allergic diseases, which currently have no cure. This could potentially lead to a significant reduction in allergy symptoms and improve the quality of life for affected individuals.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment option that effectively alleviates severe allergic symptoms and improves patients' quality of life.
How similar studies have gone: While there have been advancements in allergy treatments, this specific approach targeting IgE-producing B cells is novel and has not been extensively tested in clinical settings.
Where this research is happening
-
Cellergy Pharma
Wilmington, United States Active
Researchers
- Principal investigator: Ma, Zhengyu — Cellergy Pharma
- Study coordinator: Ma, Zhengyu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.